Literature DB >> 11031225

Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time. In vivo insights from stable-isotope studies.

J Pietzsch1, P Lattke, U Julius.   

Abstract

5-Hydroxy-2-aminovaleric acid (HAVA) has been suggested to be a specific marker of oxidation of apolipoprotein (apo) B-100 proline (Pro) and arginine (Arg) side-chain residues in low density lipoprotein (LDL) in vitro. Here we describe the application of sensitive mass spectrometric techniques to the characterization of Pro/Arg-modified apoB-100 in LDL(1) (S(f) 7 to 12) and LDL(2) (S(f) 0 to 7) in vivo. We studied 7 subjects with familial defective apoB-100 (FDB) and 8 normolipidemic controls. In FDB subjects, the presence of a mutant apoB-100 (FDB(3500Q)) in LDL markedly reduced its affinity for the LDL receptor, leading to increased residence times (RTs) of LDL(1) (65+/-21 versus 32+/-12 hours, P<0.005) and LDL(2) (230+/-40 versus 53+/-7 hours, P:<0.001) when compared with controls, as determined by stable-isotope turnover studies. LDL(1) HAVA content was not different between the groups (FDB, 0.004+/-0. 001 mol/mol apoB-100 versus controls, 0.003+/-0.001 mol/mol apoB-100, P=0.200). LDL(2) HAVA content was higher in FDB subjects (0. 374+/-0.088 versus 0.013+/-0.002 mol/mol apoB-100, P<0.001). In both groups, LDL(2) HAVA was positively associated with LDL(2) RT (FDB, r=0.893, P:=0.003; controls, r=0.976, P=0.000) and negatively correlated with LDL(2) alpha-tocopherol content (FDB, r=-0.929, P=0. 003; controls, r=-0.903, P=0.002). No significant correlations could be found between LDL(1) HAVA, LDL(1) RT, and alpha-tocopherol, respectively. The low LDL(1) HAVA content observed in both FDB and control groups was thought to be due to the relatively lower RT as well as the higher alpha-tocopherol content of these lipoproteins. In contrast, LDL(2) seemed to be strongly prone to direct oxidation of apoB-100 in vivo. The longer these particles linger in the circulation, the more apoB-100 Pro/Arg residues become modified.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11031225     DOI: 10.1161/01.atv.20.10.e63

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

Review 1.  Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.

Authors:  Heidi Noels; Michael Lehrke; Raymond Vanholder; Joachim Jankowski
Journal:  Nat Rev Nephrol       Date:  2021-05-10       Impact factor: 28.314

2.  Glycoxidised LDL isolated from subjects with impaired glucose tolerance increases CD36 and peroxisome proliferator-activator receptor gamma gene expression in macrophages.

Authors:  J Graessler; J Pietzsch; T Westendorf; U Julius; S R Bornstein; S Kopprasch
Journal:  Diabetologia       Date:  2007-03-23       Impact factor: 10.122

3.  Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.

Authors:  Johannes P Schwaiger; Yoshinobu Nakada; Ramona Berberich; Katsunori Ikewaki; Benjamin Dieplinger; Emanuel Zitt; Ulrich Neyer; Hermann Salmhofer; Florian Kronenberg; Paul Koenig; Hans Dieplinger
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 8.237

4.  Measurement of 5-hydroxy-2-aminovaleric acid as a specific marker of metal catalysed oxidation of proline and arginine residues of low density lipoprotein apolipoprotein B-100 in human atherosclerotic lesions.

Authors:  J Pietzsch; R Bergmann
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

5.  The protective effects of HDL and its constituents against neutrophil respiratory burst activation by hypochlorite-oxidized LDL.

Authors:  Steffi Kopprasch; Jens Pietzsch; Juergen Graessler
Journal:  Mol Cell Biochem       Date:  2004-03       Impact factor: 3.396

6.  LDL-Based Lipid Nanoparticle Derived for Blood Plasma Accumulates Preferentially in Atherosclerotic Plaque.

Authors:  Christian A Boada; Assaf Zinger; Scott Rohen; Jonathan O Martinez; Michael Evangelopoulos; Roberto Molinaro; Madeleine Lu; Ramiro Alejandro Villarreal-Leal; Federica Giordano; Manuela Sushnitha; Enrica De Rosa; Jens B Simonsen; Sergey Shevkoplyas; Francesca Taraballi; Ennio Tasciotti
Journal:  Front Bioeng Biotechnol       Date:  2021-12-01

7.  Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin.

Authors:  Naila Rabbani; Madhu Varma Chittari; Charles W Bodmer; Daniel Zehnder; Antonio Ceriello; Paul J Thornalley
Journal:  Diabetes       Date:  2010-01-12       Impact factor: 9.461

Review 8.  The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus.

Authors:  Isabella Bonilha; Eric Hajduch; Beatriz Luchiari; Wilson Nadruz; Wilfried Le Goff; Andrei C Sposito
Journal:  Metabolites       Date:  2021-11-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.